22ND ANNUAL INTERNATIONAL CONGRESS ON HEMATOLOGIC MALIGNANCIES®: FOCUS ON LEUKEMIAS, LYMPHOMAS & MYELOMA
The Diplomat HotelFLORIDA, USA Visit the Venue to read more
Now in its 22nd year, the annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma facilitates clinicians’ skills to contextualize the wealth of emerging data on how to treat hematologic malignancies, personalize treatment based upon patient and tumor characteristics, and apply novel management strategies to their practices to improve outcomes for their patients.
Back by popular demand! The 3-day meeting will once again be held from Friday through mid afternoon Sunday. As always, agenda topics will focus on methods to practically apply state-of-the-art strategies to your clinical practice settings. This engaging and highly interactive meeting will provide ample opportunity to interact with renowned experts in the management of leukemias, lymphomas, myeloma, myelodysplastic syndromes, myeloproliferative neoplasms, and benign hematologic malignancies. Our faculty will distill practice-changing evidence and recommend methods to place this information in its proper context and apply it to real-world care scenarios you encounter. In doing so, a focus will be placed on how to proactively mitigate and manage treatment-related toxicities associated with new treatment strategies.
The well-known and highly interactive Medical Crossfire® discussion panels interspersed throughout the meeting will allow attendees to explore some of the most challenging clinical situations in the management of hematologic malignancies. Many of which have have multiple potential approaches to care.
The case-based format of the Congress will challenge participants to apply new information they have learned, reflect on new practices they can bring back to their clinics to share with their peers, and ultimately improve patient outcomes in their practice settings.
This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of patients with hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of hematologic malignancies may also participate.
At the conclusion of this Congress, you should be better prepared to:
Detail methods by which clinical decision making in the management of hematologic malignancies can be personalized with the use of current and emerging biomarkers
Describe recent evidence on methods to optimize outcomes and consider them in the context of evolving treatment pathways and their application to individual patient cases
Explain practical methods to proactively mitigate and manage treatment-related toxicities so that optimized outcomes are not compromised in the management of hematologic malignancies
Evaluate new mechanistic approaches and compounds undergoing clinical investigation for the management of hematologic malignancies
State the therapeutic implications of recent evidence on evolving treatment paradigms for patients with hematologic tumors
Hot Topics for 2018:
Key biomarkers to consider in myeloma management
CAR-T cells and other immunotherapeutic strategies to treat hematologic malignancies
New clinical considerations for frontline and maintenance strategies for follicular lymphoma
New chronic lymphocytic leukemia agents: what patient and drug characteristics will inform sequencing decisions in relapsed/refractory disease
Novel therapies in acute leukemias and how they may alter treatment standards
Paradigm-changing strategies in the management of myeloproliferative neoplasms
Group registrations not allowed
Accompanying persons not allowed
We don’t accept Online Abstracts
3555 South Ocean Drive
Hollywood, FL 33019
Physicians' Education Resource, LLC
Physicians' Education Resource, LLC